CoreAge Rx vs HealthRX
Two GLP-1 desks, one scoreboard. We put CoreAge Rx and HealthRX head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 86 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
That doesn't make HealthRX a bad call — it's best for readers who want an accredited, physician-supervised program with a needle-free oral tablet option on either molecule — and value a legitscript trust signal, while accepting that some tiers are company-stated. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | HealthRX | |
|---|---|---|
| Brief Score | 94/100 (A) | 86/100 (B) |
| Semaglutide | $149/mo | $189/mo |
| Tirzepatide | $349/mo | $349/mo |
| Coverage | All 50 states | Not publicly listed |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.
HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.